EVO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	1.54M
Average Volume	53 146.00
Market Cap	1.85B
EPS	$-0.120 ( 2023-11-08 )
Last Dividend	$0.0722 ( 2019-01-11 )
Next Dividend	$0 ( N/A )
P/E	-18.68
ATR14	$0.0140 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2018-10-22	Anderson Mark Monroe	Buy	100 000	Stock Option (right to buy)
2018-10-22	Anderson Mark Monroe	Buy	0
2018-08-13	Smith Scott Clifford	Buy	100 000	Stock Option (right to buy)
2018-08-13	Smith Scott Clifford	Buy	0
2018-08-13	Laffer Arthur B	Buy	100 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 13 transactions
Buy: 500 392 \| Sell: 1 057

Volume Correlation

Long: -0.40 (neutral)

Short: -0.14 (neutral)

Signal:(45.366) Neutral

Eaton Vance Ohio Correlation

10 Most Positive Correlations
SOJD	0.872
RYB	0.869
WPM	0.869
NEU	0.869
KBH	0.867
SAP	0.851
GLDM	0.85
SGOL	0.85
OUNZ	0.849
BAR	0.849

10 Most Negative Correlations
DZZ	-0.856
EQNR	-0.84
GLL	-0.836
DGZ	-0.835
EBF	-0.829
DBMF	-0.817
RPM	-0.814
PKO	-0.814
PCQ	-0.814
KMLM	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eaton Vance Ohio Correlation - Currency/Commodity

0.10
( neutral )

0.02
( neutral )

0.00
( neutral )

-0.75
( moderate negative )

0.30
( neutral )

Eaton Vance Ohio Financials

Annual	2022
Revenue:	$751.45M
Gross Profit:	$174.07M (23.16 %)
EPS:	$-0.990

Q3	2023
Revenue:	$196.28M
Gross Profit:	$37.82M (19.27 %)
EPS:	$-0.220

Q2	2023
Revenue:	$170.28M
Gross Profit:	$46.32M (27.20 %)
EPS:	$-0.0844

Q1	2023
Revenue:	$191.92M
Gross Profit:	$49.78M (25.94 %)
EPS:	$-0.0815

Financial Reports:

No articles found.

Eaton Vance Ohio Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Eaton Vance Ohio Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 2.32 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0561	2001-01-05
Last Dividend	$0.0722	2019-01-11
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	221	--
Total Paid Out	$14.33	--
Avg. Dividend % Per Year	0.00%	--
Score	3.15	--
Div. Sustainability Score	2.32
Div.Growth Potential Score	0
Div. Directional Score	0.500	--

Next Divdend (Est)
(2024-06-25)

$0 Estimate 0.00 %

Dividend Stability

0.16 Bad

Dividend Score

3.15

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$1.008	24.50%
2005	$1.024	55.70%
2006	$0.704	34.50%
2007	$0.650	153.20%
2008	$0.738	177.80%
2009	$0.814	150.70%
2010	$0.966	61.90%
2011	$0.857	41.40%
2012	$0.832	54.40%
2013	$0.793	45.30%
2014	$0.732	28.90%
2015	$0.732	32.70%
2016	$0.570	25.20%
2017	$0.576	14.20%
2018	$0.495	6.05%
2019	$0.0722	0.71%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.119	1.500	-2.39	-3.58	[0 - 0.5]
returnOnAssetsTTM	-0.0424	1.200	-1.412	-1.694	[0 - 0.3]
returnOnEquityTTM	-0.0815	1.500	-2.02	-3.02	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.16	0.800	4.18	3.34	[1 - 3]
quickRatioTTM	1.932	0.800	3.34	2.67	[0.8 - 2.5]
cashRatioTTM	1.150	1.500	4.72	7.08	[0.2 - 2]
debtRatioTTM	0.261	-1.500	5.65	-8.47	[0 - 0.6]
interestCoverageTTM	-0.0559	1.000	-1.132	-1.132	[3 - 30]
operatingCashFlowPerShareTTM	-0.104	2.00	-0.0346	-0.0691	[0 - 30]
freeCashFlowPerShareTTM	-1.088	2.00	-0.544	-1.088	[0 - 20]
debtEquityRatioTTM	0.516	-1.500	7.94	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.271	1.000	8.82	8.82	[0.2 - 0.8]
operatingProfitMarginTTM	-0.000583	1.000	-2.01	-2.01	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.0312	1.000	-1.284	-1.284	[0.2 - 2]
assetTurnoverTTM	0.354	0.800	-0.970	-0.776	[0.5 - 2]
Total Score				2.32

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-13.26	1.000	-1.440	0	[1 - 100]
returnOnEquityTTM	-0.0815	2.50	-1.296	-3.02	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.088	2.00	-0.363	-1.088	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.104	2.00	-0.0346	-0.0691	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0331	1.500	-3.11	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0230	1.000	-3.07	0	[0.1 - 0.5]
Total Score				-1.322

Eaton Vance Ohio

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.